VRCA: Verrica Pharmaceuticals Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
43 institutions reported holding $28.45M of Verrica Pharmaceuticals Inc. on Form 13F (39 the quarter before). 8 opened a new position and 5 sold out. Shares held by institutions: -3%.
| Largest holders | Shares | Value |
|---|---|---|
| Caligan Partners LP | 923,910 | $5.65M |
| CANNELL CAPITAL LLC | 783,923 | $4.80M |
| Affinity Asset Advisors, LLC | 707,338 | $4.33M |
| Velan Capital Investment Management LP | 471,559 | $2.89M |
| ARMISTICE CAPITAL, LLC | 426,304 | $2.61M |
| BOOTHBAY FUND MANAGEMENT, LLC | 280,734 | $1.72M |
| VANGUARD CAPITAL MANAGEMENT LLC | 279,310 | $1.71M |
| Mariner, LLC | 207,230 | $1.27M |
| GEODE CAPITAL MANAGEMENT, LLC | 138,160 | $846K |
| BlackRock, Inc. | 74,344 | $455K |
Clinical trial readouts
4 Phase 2 or 3 trials by Verrica Pharmaceuticals Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-11 (est.) | VP-102 | Common Warts | Phase 3 | 302 | Enrollment complete | NCT07246590 |
| 2027-04 (est.) | VP-102 | Common Warts | Phase 2 | 30 | Not yet recruiting | NCT07881952 |
| 2027-05 (est.) | VP-102 (US) / TO-208 (Japan) | Common Warts | Phase 3 | 300 | Recruiting | NCT07637734 |
| 2027-11 (est.) | Cantharidin | Common Warts (Verruca Vulgaris) | Phase 3 | 250 | Recruiting | NCT07457918 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.